Biologic
Adalimumab
n=616
Certolizumab
n=21
Golimumab
n=48
Infliximab
n=1489
Natalizumab
n=3
Ustekinumabb
n=3
Vedolizumabc
n=15
Healthcare resource utilization
Patients with an inpatient hospitalization, n (%)
Baseline 126 (20.46) 4 (19.05) 11 (22.92) 504 (33.85) 1 (33.33) 0 (0) 1 (6.67)
Follow-up 50 (8.12) 1 (4.76) 2 (4.17) 172 (11.55) 0 (0) 1 (33.33) 0 (0)
Inpatient hospitalizations per patient, mean (SD)
Baseline 0.28 (0.62) 0.24 (0.54) 0.25 (0.48) 0.47 (0.79) 0.33 (0.58) 0 (0) 0.07 (0.26)
Follow-up 0.10 (0.37) 0.05 (0.22) 0.06 (0.32) 0.15 (0.46) 0 (0) 0.33 (0.58) 0 (0)
Patients with an ED visit, n (%)
Baseline 197 (31.98) 6 (28.57) 10 (20.83) 638 (42.85) 1 (33.33) 0 (0) 2 (13.33)
Follow-up 133 (21.59) 5 (23.81) 9 (18.75) 381 (25.59) 0 (0) 1 (33.33) 2 (13.33)
ED visits per patient, mean (SD)
Baseline 0.55 (1.01) 0.52 (0.98) 0.27 (0.57) 0.72 (1.08) 0.33 (0.58) 0 (0) 0.27 (0.80)
Follow-up 0.28 (0.63) 0.43 (0.93) 0.19 (0.39) 0.38 (0.82) 0 (0) 0.33 (0.58) 0.20 (0.56)
Patients with outpatient visit, n (%)
Baseline 615 (99.84) 21 (100) 48 (100) 1483 (99.60) 3 (100) 3 (100) 15 (100)
Follow-up 613 (99.51) 21 (100) 48 (100) 1486 (99.80) 3 (100) 3 (100) 15 (100)
Outpatient visits per patient, mean (SD)
Baseline 15.84 (10.48) 15.52 (12.79) 15.10 (11.66) 17.22 (12.52) 23.00 (12.53) 16.67 (6.66) 19.87 (10.60)
Follow-up 15.35 (12.16) 19.43 (16.19) 15.29 (13.14) 22.62 (12.56) 32.00 (19.97) 18.33 (9.45) 26 (10.60)
Costs, US$ 2015, mean (SD)
Inpatient hospitalization costs per patient
Baseline 5237.16 (22 173.03) 2572.62 (5790.60) 23 005.11 (140 362.91) 9777.73 (25 098.06) 2932.86 (5079.87) 0 (0) 865.41 (3351.72)
Follow-up 1556.97 (6890.84) 482.80 (2212.46) 729.87 (3800.02) 3283.48 (20 105.26) 0 (0) 2336.22 (4046.44) 0 (0)
ED visit costs per patient
Baseline 1038.43 (2343.31) 780.88 (1975.45) 490.31 (1365.25) 1400.01 (3427.13) 6829.45 (11 828.95) 0 (0) 369.12 (999.17)
Follow-up 600.47 (1749.04) 1528.11 (3226.87) 351.29 (903.86) 764.27 (2324.72) 0 (0) 253.86 (439.70) 282.35 (943.82)
Outpatient visit costs per patient
Baseline 6958.17 (12 328.91) 7674.21 (9235.38) 5884.37 (7294.03) 10 125.67 (19 252.36) 31 379.25 (19 129.65) 4916.36 (2414.85) 16 312.07 (21 577.52)
Follow-up 4627.61 (6811.83) 6128.68 (6785.56) 3746.75 (4496.06) 9033.33 (12 980.08) 12 401.00 (2447.28) 2645.23 (2211.82) 34 620.88 (28 022.13)
Total medical costs per patient
Baseline 15 092.62 (29 553.30) 12 276.04 (11 549.75) 31 145.25 (142 309.15) 23 174.47 (32 421.13) 41 152.04 (15 789.84) 5276.74 (2135.49) 18 866.09 (22 377.73)
Follow-up 7774.36 (11 875.97) 9022.00 (8764.70) 5552.71 (7653.54) 14 522.95 (26 152.63) 12 559.75 (2518.88) 5323.34 (5959.76) 36 653.80 (30 519.07)
Pharmacy costs per patient
Baseline 7656.26 (7809.05) 7435.10 (6597.44) 7738.25 (6266.00) 6214.10 (6675.97) 29 617.14 (12 089.04) 2237.84 (3077.25) 7942.91 (6995.66)
Follow-up 48 591.53 (16 081.84) 38 276.48 (9162.45) 55 948.19 (11 963.48) 45 710.70 (30 751.68) 76 979.14 (16 852.84) 53 905.11 (20 863.60) 35 620.01 (54 465.94)
Medical and pharmacy costs per patient
Baseline 22 748.88 (30 289.32) 19 711.14 (13 912.50) 38 883.50 (142 544.70) 29 388.58 (33 327.49) 70 769.18 (10 588.51) 7514.57 (5168.32) 26 809.01 (22 351.87)
Follow-up 56 365.90 (21 357.74) 47 298.48 (14 953.62) 61 500.90 (14 444.79) 60 233.64 (40 682.34) 89 538.89 (19 025.45) 59 228.45 (25 054.55) 72 273.81 (46 912.99)